---
title: "InnoCare Pharma Reports Strong Orelabrutinib Data at ESMO"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/303303500.md"
description: "InnoCare Pharma reported strong updated data for orelabrutinib at ESMO. For marginal zone lymphoma (MZL), the combination therapy showed an overall response rate of 89.5% and a 12-month progression-free survival of 95.2%. In relapsed/refractory chronic lymphocytic leukemia (R/R CLL), it achieved a 93.8% ORR with a median PFS of 50.8 months. The drug demonstrated manageable safety with no atrial fibrillation observed, highlighting its potential as a competitive BTK inhibitor."
datetime: "2026-10-28T00:30:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/303303500.md)
  - [en](https://longbridge.com/en/news/303303500.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/303303500.md)
generator: "portal-rs"
---

# InnoCare Pharma Reports Strong Orelabrutinib Data at ESMO

InnoCare reported updated orelabrutinib results: MZL combo ORR 89.5% (CRR 73.7%), 12‑mo PFS 95.2%; R/R CLL ORR 93.8% with median PFS 50.8 months; and real‑world MZL maintenance deepened responses. Safety reported as manageable with no atrial fibrillation noted.

**Material Details**

| # | Detail                             | AI Analyst View                                                                     |
| - | ---------------------------------- | ----------------------------------------------------------------------------------- |
| 1 | MZL ORR 89.5%, CRR 73.7% (ZOOM)    | High frontline efficacy may support broader adoption and label expansion prospects. |
| 2 | MZL 12-mo PFS 95.2%                | Early durability signal; supports sustained benefit in first-line setting.          |
| 3 | R/R CLL ORR 93.8%, PFS 50.8 mo     | Competitive long-term efficacy strengthens positioning vs other BTKis.              |
| 4 | No atrial fibrillation observed    | Favorable safety could be a differentiator vs some BTK inhibitors.                  |
| 5 | Real-world MZL CR conversion 66.7% | RW evidence showing deepened responses can aid physician uptake.                    |

**Context by AI Analyst**

These data extend prior clinical results, reinforcing a trend of durable efficacy and tolerability for orelabrutinib. A larger randomized trial readout or regulatory label expansion would turn this into a stronger commercial catalyst.

Based on the original press release from InnoCare Pharma distributed by GlobeNewswire.

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Summary is based on content distributed by GlobeNewswire. Please verify any important information with the original source. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [09969.HK](https://longbridge.com/en/quote/09969.HK.md)
- [688428.CN](https://longbridge.com/en/quote/688428.CN.md)

## Related News & Research

- [InnoCare Doses First Patient in Phase I Trial of Cancer Drug ICP-B381 in China](https://longbridge.com/en/news/305175446.md)
- [InnoCare's Orelabrutinib Combination Shows 89.5% Response Rate in Phase 2 Marginal Zone Lymphoma Trial](https://longbridge.com/en/news/303302918.md)
- [InnoCare's Orelabrutinib Combination Shows 100% Response Rate in Preliminary Phase 2 MZL Results](https://longbridge.com/en/news/302066175.md)
- [InnoCare Doses First Patient in Phase III Trial of Mesutoclax Against Venetoclax in AML](https://longbridge.com/en/news/304782299.md)
- [Three Orelabrutinib Studies Presented in Oral Sessions at the 88th Annual Meeting of the Japanese Society of Hematology](https://longbridge.com/en/news/302067089.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**